leisure time -WSS

leisure time

author：entertainment 2025-10-01 23:00:04 - browse：8482

ADAM FEUERSTEIN/STAT

CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor interest in an antibody-drug conjugate candidate, or ADC, called CRB-701 with the potential to be better tolerated than Padcev, an ADC treatment bladder cancer that Pfizer acquired as part of its $43 billion Seagen deal.

On Saturday, Corbus updated results from an early, dose-finding study of CRB-701, showing an overall response rate of 28% from 25 evaluable patients. Closer attention is being paid to the subset of 15 patients treated at three therapeutically active doses, where the overall response rate (all partial tumor shrinkage) was 40%. All of the responses were seen in bladder cancer (where Padcev is approved) and in cervical cancer.

The data, from a study conducted in China, were presented in a poster session at the annual meeting of the American Society of Clinical Oncology.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： What causes rare myocarditis in young men after Covid vaccines?

focus

WSS

STAT Report: Patient voices and perspectives

STAT Report: Patient voices and perspectives

Search called off for baby washed away in Pennsylvania flash flood

Readers respond to H5N1 and livestock movements, and more

Wearables generate powerful data but its not useful to doctors, yet

New lawsuit accuses health insurer Cigna of denying claims in bulk

entertainment

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Psychedelics group wrestles with new pharma identity

Wearables generate powerful data but its not useful to doctors, yet

New air purifier tech could be key to improving indoor air quality

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Dobbs anniversary: the lost opportunity of abortion as health care

Venture capitalist Bob Kocher on the state of digital health

The high cost of giving birth even with insurance

Democrats decry new health bill for going easy on private equity

Medicare details structure of new drug price negotiation program

New lawsuit accuses health insurer Cigna of denying claims in bulk

entertainment

Venture capitalist Bob Kocher on the state of digital health

Second House panel advances two

Readout LOUD podcast: Live from STAT Breakthrough Summit West

When prostate cancer spreads, where it goes matters

Arc Institute generative AI designs new CRISPR systems

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

hotspot

focus

explore

entertainment